*Division of Cognitive Neurology, Department of Neurology
†Division of General Internal Medicine, Department of Internal Medicine
§Department of Statistics
∥Division of Neuropsychology, Department of Psychiatry, Ohio State University, Columbus, OH
‡Department of Radiology, Neurology and Psychology at the Thompson Center, University of Missouri, Columbia, MO
Funding for the study was provided by an Investigator Initiated Grant from Eisai/Pfizer, Inc. Douglas W. Scharre and Maria Kataki have received Grants in excess of $10,000 per year from Eisai for research using donepezil as part of a nationwide sponsor initiated study, which is not related to our study described in this manuscript. Douglas W. Scharre and David Beversdorf have received honoraria not in excess of $10,000 per year from Eisai/Pfizer for speaker bureau events regarding their product donepezil.
Reprints: Douglas W. Scharre, MD, Department of Neurology, 395 West 12th Avenue, 7th Floor, Columbus, OH 43210 (e-mail: [email protected]).
Received for publication October 2, 2008; accepted May 7, 2009
Disclosure: For all authors, there are no commercial associations with Eisai or Pfizer that might pose a conflict of interest in connection with this submitted article. There are no other potential or real conflicts of interest for any of the author. The sponsors (Eisai/Pfizer, Inc) had no role in the design or development of the SAGE test. They had no role in the study's design, conduct, methods, subject recruitment, data collections, management, analysis, or interpretation of the data. They did not participate in the preparation, review, or approval of the manuscript.
